# Phase I Combination Ixabepilone + Cisplatin

> **NCT00832117** · PHASE1 · COMPLETED · sponsor: **R-Pharm** · enrollment: 30 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Ixabepilone
- **DRUG:** Cisplatin
- **DRUG:** Ixabepilone
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00832117
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832117, "Phase I Combination Ixabepilone + Cisplatin". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00832117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*